BCL2L1 and small cell lung carcinoma: For example, by targeting BCL-XL to the Von Hippel-Lindau E3 ligase, which is minimally expressed in platelets, the PROTAC DT2216 resulted in reduced thrombocytopaenia and enhanced activity with chemotherapeutics in solid cancer xenograft models of SCLC, triple-negative breast cancer, prostate, colon and liver cancers compared with Navitoclax [150].